Compugen ( (CGEN) ) has released its Q2 earnings. Here is a breakdown of the information Compugen presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Compugen Ltd. is a clinical-stage cancer immunotherapy company that leverages AI/ML-powered computational target discovery to develop innovative treatments for cancer. The company is known for its pioneering work in predictive computational target discovery and its focus on immuno-oncology therapies.
In its second quarter of 2025, Compugen reported significant advancements in its clinical programs, including the dosing of the first patient in the MAIA-ovarian trial for COM701 and ongoing recruitment for the GS-0321 trial. The company also highlighted its collaboration with AstraZeneca, which is set to present new data at the ESMO 2025 conference.
Financially, Compugen reported a decrease in revenue to $1.3 million from $6.7 million in the same quarter of 2024, primarily due to differences in milestone payments from its partnerships. The company maintained a strong cash position with $93.9 million in cash and equivalents, ensuring operational funding into 2027. Despite a net loss of $7.3 million, Compugen continues to invest in its R&D efforts.
Strategically, Compugen is focused on advancing its differentiated immuno-oncology therapies and leveraging its Unigen™ platform for novel discoveries. The company is also preparing for a leadership transition, with Dr. Eran Ophir set to take over as CEO, positioning Compugen for future growth.
Looking ahead, Compugen remains committed to its strategic goals, with upcoming milestones including presentations at ESMO 2025 and continued progress in its clinical trials. The company’s solid financial foundation and innovative approach to cancer treatment provide a promising outlook for its future endeavors.